India pharma faces supply chain risks from Middle East conflictRising energy and shipping costs threaten drug productionFirms rely on inventory buffers but fear prolonged disruption Did our AI summary help? The pharmaceutical sector is bracing for another round of supply‑chain disruption as escalating conflict in West Asai threatens to push up logistics and energy costs, industry executives told Moneycontrol. “We are facing a Covid pandemic kind of uncertainty,” he said, pointing to rising risks around shipping routes and energy prices. For API makers, power accounts for as much as 25 percent of production costs, making them extremely sensitive to energy price spikes. Industry leaders worry that prolonged disruption could choke supplies of crucial ingredients, inflate manufacturing costs and slow production of vital generics.

Source: The North Africa Journal March 02, 2026 12:43 UTC